Skip to main content
ORGANOIDSCIENCES LTD. logo

ORGANOIDSCIENCES LTD. — Investor Relations & Filings

Ticker · 476040 ISIN · KR7476040001 KO Professional, scientific and technical activities
Open in API
Filings indexed 53 across all filing types
Latest filing 2026-01-02 Declaration of Voting R…
Country KR South Korea
Listing KO 476040

About ORGANOIDSCIENCES LTD.

https://organoidrx.com/en/

ORGANOIDSCIENCES LTD. is a biotechnology company specializing in organoid-based technologies for drug development and regenerative medicine. The company develops next-generation cell therapies and treatments for incurable diseases by creating three-dimensional cell cultures that replicate the structure and function of human organs. Its core offerings include an Organoid-Based Regenerative Therapeutics Platform to overcome the limitations of conventional therapies and an evaluation platform for assessing drug efficacy and toxicity, providing an alternative to animal models. Additionally, the company has developed the Polaris Platform for evaluating immunotherapy sensitivity. ORGANOIDSCIENCES aims to provide innovative solutions for precise and proactive care, shifting the paradigm in the therapeutics market.

Recent filings

Filing Released Lang Actions
임시주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement of the results of an Extraordinary General Meeting (EGM) for Organoid Sciences. It details the resolutions passed, including amendments to the articles of incorporation, the appointment of directors, and the granting of stock options. This falls under the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-01-02 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 95% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options). It details the issuance of stock options to employees/directors, including the number of shares, exercise price, and legal basis. This type of disclosure regarding capital structure changes and equity-based compensation is classified as a regulatory filing under the RNS category, as it does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for general capital changes).
2026-01-02 Korean
대표이사변경
Board/Management Information Classification · 100% confidence The document is a formal announcement regarding a change in the company's representative director (CEO). It details the transition from a single representative to co-representative directors, provides the effective date, the reason for the change, and the background of the new appointee. This falls directly under the category of board and management changes.
2026-01-02 Korean
본점소재지변경
Regulatory Filings Classification · 95% confidence The document is a short, formal announcement regarding a change in the company's registered office address (headquarters). It provides the old address, new address, reason for the change, and the effective date. Since this is a corporate administrative announcement that does not fit into specific financial reporting categories like earnings or dividends, and it is a regulatory disclosure, it falls under the general regulatory filing category.
2026-01-02 Korean
투자판단관련주요경영사항(임상시험계획승인신청) (자가 성체줄기세포유래 장 오가노이드(ATORM-C)의 제1상 임상시험계획 승인신청)
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from Organoid Sciences regarding the submission of a Phase 1 clinical trial application (IND) to the Ministry of Food and Drug Safety (MFDS). It details the trial name, purpose, methodology, and potential risks. Since it is a specific regulatory announcement regarding clinical trial status and does not fit into categories like financial reports, dividends, or M&A, it is classified as a general regulatory filing.
2025-12-30 Korean
[기재정정]주주총회소집결의
AGM Information Classification · 99% confidence The document is a formal regulatory filing titled '주주총회소집결의' (Resolution for Convening a General Meeting of Shareholders) and a subsequent '정정신고' (Correction Report). It details the agenda for an upcoming Extraordinary General Meeting, including the election of directors and amendments to the articles of incorporation. This type of document is a standard proxy solicitation and information statement provided to shareholders to inform them of meeting details and agenda items, which falls under the 'Proxy Solicitation & Information Statement' category.
2025-12-18 Korean

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.